rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    VTVT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      VTv Therapeutics: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceVTVT
      vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

      Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) completed enrollment with 166 participants randomized; topline results expected mid 2027 Randomized the first participant in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in individuals with T1D who use hybrid closed-loop (HCL) insulin delivery systems Company hosted a Key Opinion Leader (KOL) event in October, highlighting cadisegliatin and its potential to address hypoglycemia in people wit

      Nov 5Yahoo FinanceVTVT
      vTv Therapeutics begins trial of cadisegliatin in T1D patients
      Oct 27Investing.comVTVT
      vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems
      Oct 27Yahoo FinanceVTVT
      vTv Therapeutics Inc. (VTVT) Discusses Hypoglycemia Burden in Type 1 Diabetes and Cadisegliatin Phase 3 Program - Slideshow (NASDAQ:VTVT) 2026-10-21
      Oct 21Seeking AlphaVTVT
      vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia
      Oct 21Yahoo FinanceVTVT
      vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026
      Oct 10Yahoo FinanceVTVT
      Exclusive BAC Article: vTv Therapeutics; Mid-2027 Topline Data CATT1 Cadisegliatin T1D, HPPD Orphan Drug Designation For SCD, And Catalysts (NASDAQ:VTVT)

      I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be vTv Therapeutics (VTVT).

      Oct 8Seeking AlphaVTVT
      vTv Therapeutics stock jumps on FDA orphan drug status
      Oct 8Investing.comVTVT
      vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
      Oct 7Yahoo FinanceVTVT
      vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026

      HIGH POINT, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 20, 2026, at 2:30 PM ET. To register, click here. The event will feature leading T1D experts Schafer Boeder, MD (Paradigm Clinical Research, University of California San Diego), Klara Kle

      Oct 6Yahoo FinanceVTVT
      vTv Therapeutics completes Phase 3 enrollment for T1D drug
      Oct 6Investing.comVTVT
      H.C. Wainwright Sticks to Its Buy Rating for vTv Therapeutics (VTVT)

      Detailed price information for Vtv Theraptcs Cl A (VTVT-Q) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailVTVT
      vTv Therapeutics at H.C. Wainwright conference: CADI advances
      Sep 16Investing.comVTVT
      vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      HIGH POINT, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule

      Sep 15Yahoo FinanceVTVT
      Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT)

      Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

      Sep 3The Globe and MailKYMRVTVT
      vTv Therapeutics to Participate in September Investor Conferences

      HIGH POINT, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in September: H.C. Wainwright 28th Annual Global Investment ConferenceFormat: Fireside Chat and one-on-one investor meetingsDate: Wednesday, September 16, 2026Time: 10:00-10:30 AM ETLocation: Ne

      Sep 2Yahoo FinanceVTVT

      This is the newest page. Registered accounts read further back.